News
SGMO
0.5115
+5.44%
0.0264
Weekly Report: what happened at SGMO last week (0408-0412)?
Weekly Report · 4d ago
Weekly Report: what happened at SGMO last week (0401-0405)?
Weekly Report · 04/08 09:24
Biotech Roundtable: Who will bring the next CRISPR drug to market?
Healthcare Biotech Roundtable: Who will bring the next CRISPR drug to market? CRisPR gene editing technology has been heralded as a revolutionary breakthrough in drug development. Last fall, the FDA approved the first CRISpr product for the US market. Seeking Alpha asked three analysts to weigh in on the technology and companies working in it.
Seeking Alpha · 04/02 15:36
Weekly Report: what happened at SGMO last week (0325-0329)?
Weekly Report · 04/01 09:24
Weekly Report: what happened at SGMO last week (0318-0322)?
Weekly Report · 03/25 09:25
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Sangamo Therapeutics, Inc. Shares have retraced a considerable 36% in the last month. The company's price-to-sales ratio of 0.8x is lower than the industry average. Sangamo has been growing revenue less than most other companies in the biotech industry. The low P/S ratio is typical of a company expected to perform poorly in the future.
Simply Wall St · 03/23 14:12
12 Health Care Stocks Moving In Friday's Intraday Session
IMAC Hldgs (NASDAQ:BACK) shares moved upwards by 91.5% to $2.47 during Friday's regular session. The company's Q4 earnings report came out yesterday. Virios Therapeutics shares increased by 37.98% and Ontrak shares rose by 35.03% in the same session.
Benzinga · 03/22 17:31
Sangamo Therapeutics Shares Drop 15% After $24M Offering Prices
Sangamo Therapeutics shares were down 14% to 83 cents after the company entered a securities purchase agreement with institutional investors. The stock closed 19% higher on Thursday, and is down 53% in the past 12 months. The company entered the offering of 24.8 million shares and warrants to buy up to 28.6 million shares.
Dow Jones · 03/22 14:34
Sangamo Therapeutics looks to raise $24M in a direct offering; shares fall
Sangamo Therapeutics looks to raise $24M in a direct offering. Shares in the company down 13.2% in pre-market trade. The company says it has entered into a securities purchase agreement for the sale of 24.76M shares and pre-funded warrants.
Seeking Alpha · 03/22 12:21
Analyst Bullish On Gene Therapy-Focused Voyager Therapeutics Sees Best In Class Potential For Its Neurogenetic Medicine Platform
H.C. Wainwright initiated coverage on Voyager Therapeutics Inc (NASDAQ:VYGR) with a Buy rating and a price target of $30. The analyst says Voyager’s TRACER capsid discovery platform has best-in-class potential for developing CNS-targeted in vivo gene therapies. The company is developing novel capsids to overcome limitations of central nervous system delivery.
Benzinga · 03/19 18:16
Sangamo Therapeutics Price Target Raised to $5.00/Share From $3.00 by HC Wainwright & Co.
Dow Jones · 03/19 10:36
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Raises Price Target to $5
Benzinga · 03/19 10:25
Analysts Offer Insights on Healthcare Companies: Biomea Fusion (BMEA), Intuitive Surgical (ISRG) and Sangamo Biosciences (SGMO)
TipRanks · 03/19 10:21
Weekly Report: what happened at SGMO last week (0311-0315)?
Weekly Report · 03/18 09:24
Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Sangamo Therapeutics, Inc. Is expected to see an 82% decline in sales to the end of 2024. Analysts have downgraded their revenue estimates for the company. The consensus is for revenues of US$32m in 2024, down from US$43m in the last 12 months. The loss per share is also expected to narrow 66% to US$0.49. Sangamo's revenues are expected to grow slower than the wider industry.
Simply Wall St · 03/16 13:17
Analysts Conflicted on These Healthcare Names: Veradigm (OtherMDRX), ADC Therapeutics (ADCT) and Sangamo Biosciences (SGMO)
TipRanks · 03/16 01:50
Sangamo Therapeutics Price Target Maintained With a $2.00/Share by RBC Capital
Dow Jones · 03/14 15:38
RBC Capital Reiterates Sector Perform on Sangamo Therapeutics, Maintains $2 Price Target
Benzinga · 03/14 15:28
Sangamo Biosciences: A Buy Rating on Strong Gene Therapy and CNS Program Prospects
TipRanks · 03/14 13:55
Truist Financial Sticks to Their Hold Rating for Sangamo Biosciences (SGMO)
Analyst consensus on Sangamo Biosciences is a Moderate Buy with an average price target of $2.25. The company’s shares closed yesterday at $0.79. Nicole Germino is ranked #2232 out of 8717 analysts.
TipRanks · 03/14 11:25
More
Webull provides a variety of real-time SGMO stock news. You can receive the latest news about Sangamo Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About SGMO
Sangamo Therapeutics, Inc. is a genomic medicines company that is developing medicines for neurological diseases. The Company's neurology preclinical development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases, and development of novel engineered adeno-associated virus (AAV) capsids to deliver its therapies to the intended neurological targets. The Company's zinc finger epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid discovery platform is expanding delivery beyond intrathecal delivery capsids, including in the central nervous system. Its clinical-stage product candidates are Isaralgagene civaparvovec, also known as ST-920, its wholly-owned gene therapy product candidate for the treatment of Fabry disease, and TX200, its wholly-owned CAR-Treg cell therapy product candidate for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation.